The company claims that NuPIAO is a highly glycosylated ESA (erythropoiesis-stimulating agent), with extended half-life and increased biologic activity.
The pre-clinical results showed a positive pharmacokinetic profile which would allow a once weekly injection schedule of NuPIAO in humans. NuPIAO is expected to be investigated to treat anemia associated with both chronic kidney disease and cancer.
Jing Lou, CEO of 3SBio, said: “This submission represents another important milestone in our effort to extend our EPO franchise and continue to serve the needs of patients in China. It is a direct result of our dedicated R&D effort to generate an innovative pipeline and create long term value for shareholders.”